Article

Ten Things You Didn't Know Were In The Affordable Care Act

So you think the Supreme Court upheld a law that requires most people to buy health insurance? That's only part of it. The measure's hundreds of pages touch on a variety of issues and initiatives that have, for the most part, remained under the public's radar.

Read the full story: http://tinyurl.com/bncj2ty

Source: Kaiser Health News

Related Videos
Tiara Green, MSEd
Ryan Jacobs, MD, Atrium Health Levine Cancer Institute
Kelly Harris, APRN
Jessica K. Paulus, ScD, Ontada
Rachel Dalthorp, MD
Jessica K. Paulus, ScD, Ontada
Michael Thorpy, MD
Sindhuja Kadambi, MD, MS
Matthew Callister, MD
Rachel Dalthorp, MD
Related Content
SMA spinal muscular atrophy | Image Credit: © Rochu_2008 - stock.adobe.com
July 26th 2024

Potential Biomarkers Predict Disease Severity and Treatment Response in SMA

Kyle Munz
Results from a single-center, observational, prospective study suggested that inflammatory markers could predict disease severity and treatment efficacy for patients with spinal muscular atrophy (SMA).
Managed Care Cast: Frameworks for Advancing Health Equity
July 23rd 2024

Frameworks for Advancing Health Equity: Health Equity by Design

Giuliana Grossi
Melissa Clarke, MD, CMQ, the chief health equity officer at Elevance Health, explains "Health Equity by Design" and how Elevance Health is committed to ensuring a personalized and intentional approach for all its members.
ARTISTRY-1: Simplifying HIV Treatment for the Most Complex Cases
July 25th 2024

ARTISTRY-1: Simplifying HIV Treatment for the Most Complex Cases

Maggie L. Shaw
These 48-week data from ARTISTRY-1 build on 24-week results previously presented and show enduring efficacy of bictegravir plus lenacapavir.
Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH
July 16th 2024

Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH

A trio of experts discuss the challenges of diagnosing and managing paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening disorder.
Efanesoctocog alfa is a high-sustained factor VIII replacement therapy for the treatment of hemophilia A | image credit: Ekaterina - stock.adobe.com
July 25th 2024

Efanesoctocog Alfa Prophylaxis Promising for Pediatric Severe Hemophilia A

Kyle Munz
The phase 3, international, open-label, single-group XTEND-Kids study concluded that children with severe hemophilia A younger than 12 years benefited from treatment with efanesoctocog alfa prophylaxis.
Liz Kwo, MD, MBA, MPH, chief commercial officer, Everly Health, and faculty lecturer, Harvard Medical School
July 24th 2024

Examining Trends, Future Directions in AI and Health Care

Pearl Steinzor
Liz Kwo, MD, MBA, MPH, chief commercial officer, Everly Health, and faculty lecturer, Harvard Medical School, discusses current and future uses in digital health care.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo